medigraphic.com
ISSN 0016-3813 (Impreso)

2003, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2003; 139 (3)


Perspectivas del genoma humano en las malformaciones congénitas

Kawa-Karasik S, Saavedra-Ontiveros MD, Morán-Barroso VF, Thompson-Chagoyán OC, Kawa-Karasik S, Cornejo-Roldán LR, Fuente-del Campo A

Idioma: Español
Referencias bibliográficas: 110
Paginas: 234-254
Archivo PDF: 295.73 Kb.


FRAGMENTO

La última década se ha caracterizado por la expansión del conocimiento científico en el área de la genética, por lo que el entendimiento de los genes así como de las bases genéticas de las enfermedades ha crecido considerable-mente. Actualmente, se conocen más de 4,000 padecimientos que, como la anemia de células falciformes y la fibrosis quística son génicas, se transmiten de padres a hijos. Más aún, se sabe qué alteraciones de nuestros genes juegan un papel importante en el desarrollo de condiciones más comunes como la enfermedad isquémica del corazón, la diabetes y diversas formas de cáncer. El proyecto del genoma humano se ha abocado en desarrollar un mapa físico del genoma humano o sea, determinar la secuencia total del ADN del hombre e identificar la socalización física de todos y cada uno de los genes que componen esta secuencia. Esto presenta mapear y secuenciar los 3 billones de pares de bases que comprenden el genoma humano, lo que permitirá crear una base de datos completa de la información genética de nuestra especie


REFERENCIAS (EN ESTE ARTÍCULO)

  1. I. Aspectos moleculares del genoma humano

  2. Darnell J, Lodish H, Baltimore M. Molecular Cell Biology, 2d ed. Scientific American Books;1990.

  3. Davidson E, Britten R. Organization, transcription and regulation in the animal genome. Quart Rev Biol 1973;48:565-613.

  4. McClintock B. Chromosome organization and genetic expression. Cold Spring Harbor Symp Quant. Biol. 1951;16:14-47.

  5. Lander ES, Botstein D. Strategies for study in heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphism. Proc Natl Acad Sci USA 1986;83:7353-7357.

  6. Friedman T. Progress toward human genetie therapy. Science. 1989;244:1257-1281.

  7. National Research Council: mapping and sequencing the human genome. Washington D.C., National Academy Press, 1988.


  9. II. Aspectos clínicos en craneosinostosis

  10. Cohen MM Jr. Structural biology and correlates of craniosynostosis. Am J Med Gen 1993;47:581-616.

  11. Gorlin RJ, Cohen MM Jr, Levin LS. Syndromes of the head and neck. 3rd ed. Oxford: University Press; 1990. P. 325-360.

  12. The London Dysmorphology Database. [CD - Room]. Winter RM and Baraitser M. Oxford: University Press; 1996.

  13. OMM (1999) Online Meendelian Inheritance in Man. Center for Medical Genetics, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md). World Wide Web URL: http://www3.nicbi.nih.gov/omim

  14. Anderson PJ, Hall CM, Evans RD, jones BM, Hayward RD. Hand anomalies in Crouzon Syndrome. Skeletal Radiol 1997;26:113-115.

  15. Cohen MM Jr and MacLean RE, editors. Craniosynostosis. Second Ed. Oxford: University Press; 2000.


  17. III. Aspectos nutricionales en las malformaciones craneofaciales

  18. Iqbal MM. Prevention of neural tube defects by periconceptional use of folic acid. Pediatr Rev. 2000;21:58-66.

  19. Young DL, Scbneider RA, Hu D, Helms JA. Genetic and teratogenic approaches to craniofacial development. - Cnt Rev Oral Biol infed - 2000;11:304-17.

  20. Robert L, Brent. Addressing environmentally caused human birth defects. Pediatr Rev 2001;22:153-165.

  21. Hernández AJ, Cortes CG, Aldana VC, Ramírez HA. Incidencia de malformaciones congénitas en el Hospital de Gineco-Pediatría No. 48 en León Guanajuato. Bol Med Hosp Infant Mex 1996;53:117-222.

  22. Rodríguez MM, Guerrero RJ, Parra QM, Segura PM, Levario CM, Sotelo HI. Deficiencia de folatos y su asociación con defectos del tubo neural. Salud Pub Mex 1998;40;474-80.

  23. Bishop DT. Multifactorial inheritance In: Principles and practice of medical genetics. 2nd ed. Churchill Livingstone Edimburg 1990:165-74 Young DL.

  24. Saltou M, Sugal S, Tanaka T. Inhibition of skin development by targered expression of a dominant-negative retinoic acid. Nature 1995;374:159-162.

  25. Farennec L, Cals MJ. The biological effects of retinoids on cell differentiation, and proliferation. J Clin Chem Clin Biochem 1988;26:479-489.

  26. De Luca LM. Retinoids and their receptor in differentiation, embryogenesis and neoplasia FAJEB J 1991;5:2924-2933.

  27. Parkinson DR, Smith MA, Cheson BD, Stevenson HC, Friedman MA. Trans retinoic acid and related differentiation agents. Semin Oncol 1992;19:724-741.

  28. Emmanouil-Nikoloussi EN, Goret-Nicaise M, Foroglou CH, Katsarma E, Dhem A, Dourov N, Persaud TV, Thliveris JA. Craniofacial abnormalities induced by retinoic acid: a preliminary histological and scanning electron microscopic (SEM) study. Exp Toxicol Pathol - 2000;52:445-453.

  29. Shenefelt RE. Morphogenesis and malformations in hamsters caused by retinoic acid: relation to dose and stage of treatment. Teratology 1972;5:103-118.

  30. Cohlan SQ. Congenital anomalies in the rat produced byexcessive intake of vitamin A during pregnancy. Pediatrics 1954;13:556-567.

  31. Kalter H, Warkany J. Experimental production of congenital malformations in strains of inbred mice by maternal treatment with hypervitaminosis A. Am J Pathol 1961;38-1-21.

  32. Kochhar DM. Teratogenic activity of retinoic acid. Acta Pathol Microbiol Scand 1967;70;398-404.

  33. Newell ML, Siriani JE,Shepard TH, Fantel AG, Moffet BC. Teratogenic effects of retinoic acid in pig tail monkeys (Macaca nemestrina) II. Craniofacial features. Teratology 1980;22:87-101.

  34. Yip JE, Kokich VG, Shepard TH. The effect of high dosis of retinoic acid on prenatal craniofacial development in Macaca nemestrina. Teratology 1980;21:29-38.

  35. Goodhart RS, Shils ME. Modern nutrition in health and disease, 6th. ed. Lea & Febiger Philadelphia 1980:863-864.

  36. Mutchinik O, Lisker R, Babinski V. Programa mexicano de registro y vigilancia epidemiológica de malformaciones congénitas externas. Salud Pública Mex 1988;30:88-100.

  37. Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y. Maternal multivitamin use and orofacial clefts in offspring. Teratology -2001;63(2):79-86.

  38. Bianchi F, Calzolan E, Ciulli L, Cordier S, Gualandi F, Pierini A, Mossey P. Environment and genetics in the etiology of cleft lip and cleft palate with reference to the role of folie acid. Epidemiol Prev- 2000 Jan-Feb;24(1):21-27.

  39. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med - 30-Nov-2000;343(22):1608-1614.

  40. Lammer EJ, Chen DT,Hoar RM y col. Retinoic acid embryopathy. New Engl J Med 1985;313:837-841.

  41. Laurence KM, James N, Miller MH, et al. Double-blind randomized controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J 1981;282:1509-1511.

  42. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Cauncil vitamin study. Lancet 1991;338:131-137.

  43. Smithells RW, Shephard S, Schorah CJ, et al. Possible prevention of neural tube defects by periconceptional vitamin supplementation. Lancet 1980;1:339-340.

  44. Vergel RG, Sanchez LR, Heredero BL, et al. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Frenar Diagn. 1990;10:149-152.

  45. Mulinare J, Cordero JF, Erickson D, et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA. 1988;260:3141-3145.

  46. Bower C, Stanley FJ. Dietary folate as a risk factor for neural tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989;150:613-618.

  47. Mills JL, Phoads GO, Simpson JL, et al. The absence of a relation between the periconceptional use of vitamins and neural tube defects. The National Institute of Child Health and Human Development Neural Tube Defect Study Group. N Engl J Med. 1989;321:430-435.

  48. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989;262:2847-2852.

  49. Carlson BM. Human embriology and developmental biology. Mosby St Louis M. 1994:182-203.

  50. Loffredo LC, Souza JM, Freitas JA, Mossey PA. Oral clefts and vitamin supplementation. - Cleft Falare Craniofac J- 01-Jan-2001;38(1):76-83.

  51. Tabn C. The initiation of the limb bud: Growth factors. Hox genes, and retinoid Cells 1995;80:671-674.

  52. Illnis JW, Mortlok DP. Limb development: molecular dysmorphology in at hand. Clin Genet 1998;53:337-348.

  53. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. Am J Epidemiol - 1999 Oct 1;150(7):675-682.

  54. Hartridge T, Illing HM, Sandy JR.The role of folic acid in oral clefting. Br J Ortuod -1999 Jun; 26(2):115-120.

  55. Czeizel AE, Metneki J, Dudas I. Higher rate of multiple births after periconceptional vitamin supplementation. New Eng J Med 1994;330:1687-1688.

  56. Rosado JL, Bourges H, Saint-Martin B. Deficiencia de vitaminas y minerales en México. Una revisión crítica del estado de la información II. Deficiencia de vitaminas. Salud Pública Mex 1995;37:452-461.

  57. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamines for preventing neural tube defects. Cochrane Database of Systematic Reviews 2000;2.


  59. IV. Genes involucrados en craneosinostosis sindrómicas

  60. OMIM: Online Mendelian Inheritance in Man. Center for Medical Genetics, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda1 Md.). World Wide Web URL: http://www.ncbi.nih.gov/omim

  61. Houssaint E, Blanquet PR, Champion-Arnaud P, Gesnel MO, Torriglia A, Courtois Y, et al. Related fibroblast growth factor receptor genes exist in the human genome. Proc Natl Acad Sci USA 1990;87:8180-8184.

  62. Goldfarb M. Functions of fibroblast growth factors in vertebrate development. Cytokine Growth Factor Rew 1996;7:311-325.

  63. Ornitz DM, ltoh N. Fibroblast growth factors. Genome Biol 2001;2:30005.1-3005.12.

  64. Bourgois P, Stoetzel O, Bolcato - Bellemin AL, Mattei MG, Perrin - Schmitt F. The human H-twist gene is located and encodes a b-HIH protein that is 96% similar to its murine M-twist countepart. Mammal Genome 1996;7:915-917.

  65. Ruta M, Burgess W, Givol D, Epstein J, Neiger N, Kaplow J, et. al. Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the FMS-like gene (FGL). Proc Nat Acad Sci 1989;86:8722-8726.

  66. Robin NH, Feldman GJ, Mitchell HF, Lorenz P, Wilroy RS, Zackai EH, et al. Linkage of Pfeiffer syndrome to chromosome 8 centromere and evidence for genetic heterogeneity. Hum Molec Genet 1994;3:2153-2158.

  67. Muenke M, SchelI U, Hehr A, Robín NH, Losken HW, Schinzel A, et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994;8:269-274.

  68. Roscioli T, Flanagan S, Kumar P, Masel J, Gattas M, Hyland VJ, et al. Clinical findings in a patient with FGFR1 P252R mutation and comparison with the literature. Am J Med Genet 2000;93:22-28.

  69. JC Jorde LB, Carey, Bamshad MJ, White RL. Genética Médica. En: JC Jorde LB, Carey, Bamshad MJ, White RL, editores. Biología Celular Básica: estructura y función de los cromosomas. Segunda Ed. España: Harcourt; 1999. p. 17.

  70. Dionne CA, Crumley G, BeIlot F, Kaplow JF, Searfoss G, Ruta, et al. Cloning and expression of two distinct high - affinity receptors cross-reacting with acidic and basic fibroblast growth factros. EMBO 1990;9:2685-2692.

  71. Wilkie AOM, Slaney SF, Oldrigde M, Poole MD, Ashworth GJ, Hockey A, et. al. Aped syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 1995;9:165-172.

  72. Oldridge M, Zackai EH, McDonatd - McGinn, lskei S, Morris - Kay GM, et al. De novo Alu element insertion in FCFF2 identify a distinct pathological basis for Apert syndrome. Am J Hum Genet 1999;64:446-461.

  73. Oldridge M, Lunt PW, Zackai EH, McDonald-McGinn, Muenke M, Moloney DM, et al. Genotype-Phenotype correlation for nucleotide substitutions in the IgIl - IgIIl Iinker of FGFR2. Hum Mol Genet 1997;6:137-143.

  74. Cornejo - Roldán LR, Roessler E, Muenke M. Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome. Hum Genet 1999;104:425-431.

  75. Schefer F, Anderson C Can B, Say B. Novel mutation in the FGFR2 gene at the same codon as the Crouzon syndrome mutations in a severe Pfeiffer syndrome type 2 case. Am J Med Genet 1998;75:252-255.

  76. Schell U, Hehr A, Feldman GJ, Robin NH, Zackai EH, de Die - Smulders C, et al. Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Molec Genet 1995;4:323-328.

  77. Lajeunie E, Ma HW, Bonaventure J, Munnich A, Le Merrer, Renier D. FGFR2 mutations in Pfeiffer syndrome. Nat Genet 1995;9:108.

  78. Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, Jones B, et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet 1995;9:173-176.

  79. Meyers GA, Day D. Goldberg R, Daentl DL, Przylepa KA, Abrams U, et al. FGFR2 exon lIIa and IlIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 1996;58:491-498.

  80. Paznekas WA, Ounningham ML, Howard TD, korf BR, Lipson MH, Grix AW, et al. Genetic heterogeneity of Saethre-Chotzen syndrome, due to TIWST and FGFR mutations.Am J Hum Genet 1998;62:1370-1380.

  81. Muenke M, Wilkie ACM. The metabolic & Molecular Basis of Inherited Disease. Craniosynostosis Syndromes. In: Scriver OHR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al. Editors. Eighth Ed. EUA: McGraw-HilI; 2001. p.6117-6146.

  82. Pulleyn LJ, Reardon W, Wilkes D, Rutland P, Jones BM, Hayvvard R, et al. Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Hum Genet, 1996;4:283-291.

  83. Wilkie, unpublished.

  84. Oldridge M, Wilkie ACM, Slaney SF, Poole MD, Pulleyn U, Rutland P, et al. Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum Mol Genet 1995;4:1077-1082.

  85. Park WJ, Meyers JA, Li X Theda C, Day D, Orlow SJ, et al. Novel FGFR2 mutations in Crouzon and Jackson - Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mo Genet 1995;4:1229-1233.

  86. Steinberg D, Collmann H, Schmalenberger B, Muller U. A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with Crouzon phenotype and plagiocephaly. J Med Genet 1997;34:420-423.

  87. Steinberg D, Vried G, MuIIiken JB, Múller U. The mutations in FGFR2 -associated craniosynostoses are clustered in five structural elements of immunoglobulin- Iike domain III of the receptor. Hum Genet 1998;102:145-149.

  88. Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, et al. Jackson - Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nature Genet 1994;8:275-279.

  89. Steinberg D, Mulliken JB, Múller U. Crouzon syndrome: previously unrecognized deletion, duplication, and point mutation within FGFR2 gene. Hum Mut 1996;8:386-390.

  90. Passos - Bueno MR, Sertié AL, Richieri - Costa A, alonso LG, Zatz M, Alonso N, et al. Description of a new mutation and characterization of FGFRI, FGFF2 and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses. Am J Med Genet 1998;78:237-241.

  91. Gorry MC, Preston RA, White GJ, Zhang Y, Singhal VK, Losken HW, et al. Crouzon syndrome: mutations in two splice forms of FGFR2 and a common point mutation shared with Jackson - Weiss syndrome. Hum Mol Genet 1995;4:1387-1390.

  92. Reardon W, Winter RM, Rutland P, Pulleyn U, Jones BM, Malcolm S. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994;8:98-103.

  93. Manchester DK, Allen JK, Handler M, Schafer FV. Novel FGFR2 mutation associated with a partial Aped syndrome phenotype. Am J Hum Genet 1999;65(Supp):A477.

  94. Hertz JM, Juncker I, Molhave B, Sunde L, Christensen L, Ostergaard JR, et al. Mutations in the FGFR2 - gene in Crouzon syndrome. Eur J Hum Genet 1997;5(Supp 1):155-159.

  95. Pérez-CastroAV, Wilson J, Atherr MF. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997;41;10-16.

  96. Muenke M, Gripp KW, McDonald-McGinn DM, Gaudenz K, Whitaker LA, Bartíen SP, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet 1997;60:555-564.

  97. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, et al. Mutations of the twist gene in the Saethre-Chotzen syndrome. Nat Genet 1997;15: 42-46.

  98. Bourgeois P, Bolcato-Bellemin AL, Dansa JM, Bloch-Zupan A, Yoshiba K, Stoetzel, et. al. The variable expressivity and incomplete penetrance of the twist -null heterozygous mouse phenotype resembles those of human Saethre -Chotzen syndrome. Hum Molec Genet 1998;7:945-957.


  100. V. Tratamiento quirúrgico de las craneodisostosis

  101. Gillies H, Harrison SH. Operative correction by osteotomy of recessed malar maxillary compound in a case of oxycephaly. Brit J Plast Surg, 3:123;1950.

  102. Tessier P. Ostéotomies totales de la face: síndrome d’Apert, oxycéphalies, scaphocéphalies, turricéphalies. Ann Chir Plast, 12:273;1967.

  103. Ortiz Monasterio F, Fuente del Campo A, Carrillo A. Advancement of the Orbits and the Midface in One Piece, Combined with Frontal Repositioning for the Correction of Crouzon’s Deformities. Plast Reconstr Surg 61: 507;1978.

  104. Ortiz Monasterio F, Fuente del Campo A, Vásquez A. “Planning a Craniofacial Operation”. In: Symposium on Diagnosis and Treatment of Craniofacial Anomalies. Volumen Twenty. C.V. Mosby, St. Louis. Pp 362,1979.

  105. Fuente del Campo A. “Rigid Fixation in Block Orbitofacial Advancement and Facial Bipartition Osteotomies”. In: Rigid Fixation of the Craniornaxillofacial Skeleton. Edit. Yaremchuk, M., Gruss J.S., Manson. Buttenworth- Heinemann, Baltimore. Pp.553-560;1992.

  106. Fuente del Campo A. “Colgajo de Periostio para Reconstruir el Piso Anterior del Cráneo en Cirugía Craneofacial”. Cir Plast Ibero-latinoamer. 8:127;1982.

  107. Fuente del Campo A. “Nuevo Distractor Óseo Simplificado Para la Osteogénesis Inducida de la Mandíbula. Experiencia 126 casos”. Gaceta Médica de México, 6;537;2000.

  108. Fuente del Campo A. “Rigid Fixation and Osteotomy Design in Frontal Orbital Advancement”. Clin Plast Surg 16:205;1989.

  109. Fuente del Campo A. :”Plagiocefalia Tratamiento Quirúrgico Integral”. Autor. CirPlast. Iberolatinoamer. 16:185;1990.

  110. Fuente del Campo A, Pérez de las Casas O, Ortiz Monasterio F. “Descripción y Clasificación de las Deformidades Craneofaciales. Manejo y Tratamiento de las Craneodisostosis”. Tomo II. Coiffman, F. (edir.), Texto de Cirugía Plástica Estética y Reconsatructiva. Masson-Salvat, Barcelona. Pp 1221-1234;1994.




2020     |     www.medigraphic.com